Recent News

• 06.03.2026 - Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
• 06.02.2026 - Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
• 06.02.2026 - Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
• 06.01.2026 - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.01.2026 - Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
• 05.28.2026 - Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

Recent Filings

• 05.28.2026 - 8-K Current report
• 05.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors